@article{b50762e4b0864afa8fb0abfbb5602fb6,
title = "Patient selection criteria and the FLEX Study",
author = "Herbst, {Roy S.} and Hirsch, {Fred R.}",
note = "Funding Information: RSH has received research funding from Bristol-Myers Squibb, OSI Pharmaceuticals, Genentech, AstraZeneca, and Amgen, and has served as a consultant for Bristol-Myers Squibb, OSI Pharmaceuticals, Genentech, AstraZeneca, and Imclone. FRH has received research funding from Genentech, OSI Pharmaceuticals, AstraZeneca, Syndax, Biogen Idec, Merck, and Ventana-Roche, has served as a consultant for Genentech, AstraZeneca, Merck-Serono, Lilly, and Bristol-Myers Squibb/Imclone, and is coinventor on a patent which has been licensed to Abbott about use of fluorescent in-situ hybridisation for the epidermal growth factor receptor as a biomarker.",
year = "2009",
doi = "10.1016/S0140-6736(09)60834-5",
language = "English",
volume = "373",
pages = "1497--1498",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Ltd.",
number = "9674",
}